Drug granted orphan status for follicular lymphomaFebruary 24, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
European Commission approves rituximab biosimilarFebruary 23, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Group ranks TKIs according to cardiotoxicityFebruary 17, 2017Leukemia, Myelodysplasia, TransplantationPharmacyRelated IssuesALLCML
Therapy granted PIM designation for CTCLFebruary 3, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Company withdraws MAA for pegfilgrastim biosimilarFebruary 2, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyRelated Issues
Cheap manufacture of generic cancer drugs is feasible, study showsFebruary 2, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersHematology NursingPediatricsPharmacyRelated Issues
Recent price hikes for generic cancer meds exceed 100%February 1, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyRelated Issues
CHMP recommends hybrid drug for ALL, other disordersJanuary 31, 2017Leukemia, Myelodysplasia, TransplantationPharmacyALL
Combo granted orphan designation for DLBCLJanuary 27, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
FDA approves ibrutinib to treat rel/ref MZLJanuary 20, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Pharma is gaming the system for orphan drugs, investigation suggestsJanuary 19, 2017PharmacyRelated Issues
